Berlin Heart Completes Enrollment in the EXCOR? Pediatric Ventricular Assist Device (VAD) Post Approval Study - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Berlin Heart Completes Enrollment in the EXCOR? Pediatric Ventricular Assist Device (VAD) Post Approval Study


Berlin Heart Completes Enrollment in the EXCOR® Pediatric Ventricular Assist Device (VAD) Post Approval Study

PR Newswire

THE WOODLANDS, Texas, Aug. 4, 2014 /PRNewswire/ -- The Berlin Heart Group announced today that they have completed enrollment in their Post Approval Study, the only condition of the "Humanitarian Device Exemption" (HDE) approval that Berlin Heart received for the EXCOR® Pediatric Ventricular Assist Device (VAD) on December 16 th, 2011.

Berlin Heart logo

The Berlin Heart EXCOR® Pediatric VAD is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. The system is designed to support pediatric patients of all age groups, from newborns to teenagers, and is intended to bridge patients awaiting heart transplantation from days to several months, until a donor heart becomes available. The Berlin Heart EXCOR® Pediatric VAD, which is also approved for use in Europe and Canada, is the only Ventricular Assist Device that is designed specifically for the pediatric population to be approved in the United States.

The purpose of the Post Approval Study for the EXCOR® Pediatric VAD was to evaluate whether safety and outcomes of the device in the commercial setting were comparable to the safety and outcomes of the device in the IDE study.  The "all-comers" prospective study enrolled 39 subjects who were implanted with the device per the approved labeling. Of the 39 subjects enrolled, 34 have reached an endpoint to date. As soon as the remaining subjects reach an endpoint, the study data will be analyzed and presented to the FDA.

Bob Kroslowitz, President and CEO of Berlin Heart's North American operations, said: "We are extremely pleased that we have, with the continued support of our implanting sites, been able to satisfy the final requirement of the EXCOR Pediatric approval in a very short period of time." "As the EXCOR® Pediatric had extensive use prior to the HDE approval (available to all North American sites who requested the device under compassionate use regulations), we are confident that the results of the Post Approval Study will be consistent with the IDE Study, and in some areas will trend more favorably."

About Berlin Heart

Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices (VADs) for patients of every age and body size. The company offers pumps, cannulas, and external components for internal and external use to stabilize cardiac activity in acutely ill patients. Its products are market leaders in their respective segments in Germany and in Europe. The company also manufactures the implantable left ventricular assist device INCOR®, which has been designed for long-term application in adult patients. INCOR® is not FDA-approved, but widely used in Europe.  Berlin Heart Inc., the company's US subsidiary, was founded in 2005 to support the North American centers. Further product information is available from the company website: www.berlinheart.com.

Contact:
Berlin Heart Inc.
Jennifer Braughton
200 Valleywood, Suite B100
The Woodlands, TX 77380
braughton@berlinheart.com 
Phone: 281-863-9700
Fax: 281-863-9701

Logo - http://photos.prnewswire.com/prnh/20120806/DA52722LOGO

SOURCE Berlin Heart Inc

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here